Erratum: Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma (Proc Natl Acad Sci USA (2011) 108 (17450-17455) DOI: 10.1073/pnas.1114518108);Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 42, 2011, Pages 17450-17455

  Agemy, Lilach ^a   Friedmann Morvinski, Dinorah ^b   Kotamraju, Venkata Ramana ^a   Roth, Lise ^a   Sugahara, Kazuki N ^c   Girard, Olivier M ^d   Mattrey, Robert F ^d   Verma, Inder M ^b   Ruoslahti, Erkki ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c BURNHAM INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Apoptosis; Tumor targeting; Tumor treatment

Indexed keywords

ANGIOGENESIS INHIBITOR; CYSTEINYLGLYCYLLYSYLARGINYLLYSINE; IRON OXIDE; MACROGOL; NANOPARTICLE; RHODAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG SPECIFICITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; LIVER TOXICITY; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

MUS;

EID: 80054795004     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1413457111     Document Type: Erratum

References (35)

1. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364. (Pubitemid 26272076)
2. Ferrara N, Alitalo K (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5:1359-1364.
3. Ruoslahti E, Bhatia SN, Sailor MJ (2010) Targeting of drugs and nanoparticles to tumors. J Cell Biol 188:759-768.
4. Allen TM, Cullis PR (2004) Drug delivery systems: Entering the mainstream. Science 303:1818-1822. (Pubitemid 38374867)
5. Jain RK, Gerlowski LE (1986) Extravascular transport in normal and tumor tissues. Crit Rev Oncol Hematol 5:115-170. (Pubitemid 16120471)
6. Ruoslahti E (2002) Specialization of tumour vasculature. Nat Rev Cancer 2:83-90.
7. Pasqualini R, Ruoslahti E (1996) Organ targeting in vivo using phage display peptide libraries. Nature 380:364-366. (Pubitemid 26097120)
8. Hoffman JA, et al. (2003) Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 4:383-391. (Pubitemid 37491099)
9. Javadpour MM, et al. (1996) De novo antimicrobial peptides with low mammalian cell toxicity. J Med Chem 39:3107-3113. (Pubitemid 26260315)
10. Ellerby HM, et al. (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5:1032-1038. (Pubitemid 29439574)
11. Arap W, et al. (2002) Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci USA 99:1527-1531. (Pubitemid 34136526)
12. Fantin VR, et al. (2005) A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cells. Cancer Res 65:6891-6900. (Pubitemid 41060728)
13. Karjalainen K, et al. (2011) Targeting neuropilin-1 in human leukemia and lymphoma. Blood 117:920-927.
14. Mai JC, Mi Z, Kim SH, Ng B, Robbins PD (2001) A proapoptotic peptide for the treatment of solid tumors. Cancer Res 61:7709-7712. (Pubitemid 33049352)
15. Rege K, Patel SJ, Megeed Z, Yarmush ML (2007) Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells. Cancer Res 67:6368-6375. (Pubitemid 47037520)
16. Gradishar WJ, et al. (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794-7803. (Pubitemid 46657376)
17. Haley B, Frenkel E (2008) Nanoparticles for drug delivery in cancer treatment. Urol Oncol 26:57-64.
18. Sugahara KN, et al. (2010) Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328:1031-1035.
19. Sugahara KN, et al. (2009) Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16:510-520.
20. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492-507.
21. Marumoto T, et al. (2009) Development of a novel mouse glioma model using lentiviral vectors. Nat Med 15:110-116.
22. Soda Y, et al. (2011) Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci USA 108:4274-4280.
23. Agemy L, et al. (2010) Nanoparticle-induced vascular blockade in human prostate cancer. Blood 116:2847-2856.
24. Park JH, et al. (2009) Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small 5:694-700.
25. Chi AS, Sorensen AG, Jain RK, Batchelor TT (2009) Angiogenesis as a therapeutic target in malignant gliomas. Oncologist 14:621-636.
26. Kunkel P, et al. (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61:6624-6628. (Pubitemid 32896475)
27. Marks AJ, et al. (2005) Selective apoptotic killing of malignant hemopoietic cells by antibody-targeted delivery of an amphipathic peptide. Cancer Res 65: 2373-2377. (Pubitemid 40490148)
28. Ko YT, Falcao C, Torchilin VP (2009) Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. Mol Pharm 6:971-977.
29. Standley SM, et al. (2010) Induction of cancer cell death by self-assembling nanostructures incorporating a cytotoxic peptide. Cancer Res 70:3020-3026.
30. Jain RK, et al. (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8:610-622. (Pubitemid 47093931)
31. Vredenburgh JJ, et al. (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-1259. (Pubitemid 46424067)
32. Ricci-Vitiani L, et al. (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468:824-828.
33. Wang R, et al. (2010) Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468:829-833.
34. Hendrix MJ, Seftor EA, Hess AR, Seftor RE (2003) Vasculogenic mimicry and tumourcell plasticity: lessons from melanoma. Nat Rev Cancer 3:411-421. (Pubitemid 37328845)
35. Yue WY, Chen ZP (2005) Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem 53:997-1002.